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Background: Transcatheter aortic valve implantation (TAVI) has emerged as a new
therapeutic option in high-risk patients with severe symptomatic tricuspid aortic valve
stenosis (TriAV). However, due to its speciﬁc anatomical characteristics, stenosis of
bicuspid aortic valve (BAV) is still considered a relative contraindication for TAVI.
We sought to determine whether the results of TAVI in patients with BiAV are
comparable to those with TriAV.
Methods: 385 TAVI was performed in 5 academic centers in Poland in the period
between 01.01.2009 and 31.07.2012. Among them 26 patients with BAV (6,7%) were
identiﬁed, and compared with controlled group of 78 patients with TriAV (ratio 3:1)
matched according to the perioperative risk, delivery route and type of implanted
bioprostehsis. One-year echocardiographic and clinical follow-up was performed.
Device success and end-points were deﬁned according to Valvular Academic
Research Consortium guidelines (VARC).
Results: Baseline characteristics was similar in both groups (tab.1). Valves were
successfully implanted in all patients and acute results after TAVI achieved in BAV
were similar to that accomplished in TriAV (AVA: 1.58 cm2 vs 1.61 cm2 , p¼ 0.81;
mean gradient: 12.3 mm vs 10.4 mm Hg, p¼ 0,12 and moderate-to-severe regurgi-
tation: 34,6% vs 23%, p¼0.46). All parameters remained stable during the mean 11.5
months of follow-up (AVA:1,67 cm2 vs. 1,62 cm2; mean gradient: 8,9 mm Hg vs.
12,1 mm Hg, p¼0,23 and moderate-to-severe regurgitation: 27,3% vs 25,0 %
p¼0.91). The survival rate during the long-term follow-up was 82,1% in BAV vs.
83.3% in TriAV, p¼0,94).Bicuspid n=26 Tricuspid n=78 P
Age 78,1  5,04 79,3  6,88 0,42
Gender 50% female 57% female 0,89
Euroscore 19,59  9,2 19,08  8,9 0,79
Valve type 84,6% CoreValve 80,7% CoreValve 0,91
Access type TF¼84,6%, TF¼73,1%, 0,63
DM 38,4% 35,9% 0,95
Hypertension 57,7% 65,3% 0,87
PAD 19,1% 30,8% 0,31
NYHA III+IV 76,9% 73,1% 0,81
EF 49,5% 50% 0,89
AVA 0,667 0,584 0,75
Mean gradient 57,45 52,46 0,68
Table 1. Blood Cultures
Blood Cultures Days to TAVI-PIE
Staphylococcus aureus, MRSA 13
Staphylococcus epidermidis 35
Enterococcus faecalis 38
Haemophilus parainﬂuenzae 90
Granulicatella adiacens 106
Staphylococcus epidermidis 158
Escherichia coli, ESBL 180
Enterococcus faecalis 180
Streptococcus spp. 209
Streptococcus oralis 270
Enterococcus spp. 286
Staphylococcus aureus 324
Staphylococcus hominis < 1 year
Streptococcus faecalis 390
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SConclusions: The periprocedural and mid-term clinical and echocardiographic
outcomes of TAVI in patients with BAV seem to be acceptable and fully comparable
to those achieved in TriAV patients. Paravalvular regurgitation remains a major
concern in both anatomies.
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Background: Mitral Regurgitation (MR) is common in patients undergoing TAVI.
There is conﬂicting data on the inﬂuence of preoperative MR on the outcome after
TAVI.
Methods: We analysed all patients who underwent TAVI in between January 2008
and February 2012. Data was extracted from the Swedish TAVI registry. Survival data
was available in all patients. 576 patients had reached one year follow-up and 373
patients had reached two years follow-up. Another 22 patients had incomplete data on
MR and were not analysed andanother16 patients had incomplete follow-up data andJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrwere also excluded. The Medtronic CoreValve had been used in 306 cases and the
Edwards Sapien in 270 cases. The most common access sites were transfemoral
(n¼390) and transapical (n¼165). Patients were divided into two groups according to
the degree of preoperative MR: mild group (463 patients, of which 142 patients MR
grade 0/III, 321 patients MR I/III) and moderate group (113 patients, of which 103
patients MR grade II/III, 10 patients MR III/III).
Results: There was no signiﬁcant difference between the mild and moderate MR
group in mean age (81.3 vs 82.2 years, ns), baseline serum creatinine (108 vs. 113
micromol/L, ns). However patients in the moderate MR group more often had Left
ventricular dysfunction (LVEF<35% in 21% vs. 38%, p<0.01) and more often had
severe symptoms(NYHA IV in 15%vs 26% p¼0.01).
Conclusions: In 576 TAVI patients, preoperative MR did not signiﬁcantly inﬂuence
mortality up to 2 years post-procedure. Thus it seems safe to perform TAVI in aortic
stenosis patients with concomitant mitral valve regurgitation. It remains to be studied
if preoperative MR predicts less improvement in symptoms in these elderly patients.
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Background: Prosthetic valve infective endocarditis (PIE) is a rare though serious
complication with high morbidity and mortality. We aimed to examine the epidemi-
ology, management strategies and outcomes of Transcatheter Aortic Valve Implan-
tation(TAVI)associated PIE.
Methods: Between JAN 2008 and FEB 2013, 1785 consecutive patients underwent
TAVI (1036 Edwards THV, 731 CoreValve, 18 DirectFlow) in 12 centers across Italy
and were studied retrospectively. The diagnosis of PVE was deﬁned according to the
VARC-2 criteria by applying the modiﬁed Duke deﬁnitions.
Results: Post TAVI–PIE was diagnosed in 24 patients with an overall incidence of
1.34%, 8 early (<60 days) and 16 late. Based on the Duke criteria, 58% patients had
deﬁnite and 42% probable endocarditis. The index procedure was performed trans-
femorally in 75% and transapically in 25%. In majority of cases (83%) the Edwards
THV was implanted. Mean age was 80.45.7 years and median Log EuroSCORE
¼28.6 (14.3-34). Important comorbidities included diabetes (46%), CRF (42%),
dialysis (4%), liver disease (21%), neoplasia(12%), and previous endocarditis
(4%).On echocardiography 6 patients had aortic prosthetic valve vegetations, 1 with
an associated MV vegetation, 3 had isolated MV vegetations, 2 had persistently high
aortic valve gradients, 1 had severe central AR, 1 severe paravalvular leak and 2
paravalvular abscess. Available blood culture results are shown in table. Complica-
tions of TAVI-PIE included cerebrovascular accidents (21%), multi-organ failure and
shock (29%). Management was surgical in 2 patients of whom 1 expired and the rest
(22) were managed medically of whom 14 died (9 in-hospital and 5 after discharge),
resulting in a total mortality 15/24 (63%).acts/ORAL/TAVR - Imaging B35
